12:00 AM
 | 
Aug 11, 2008
 |  BioCentury  |  Regulation

Iloperidone efficacy

Iloperidone efficacy

Vanda (NASDAQ:VNDA) conducted a four-week Phase III trial comparing iloperidone to placebo, with Geodon ziprasidone as an active control. The trial demonstrated the superiority of both iloperidone and Geodon vs. placebo. Vanda also submitted to FDA three 6-week Phase III trials conducted by Novartis (NYSE:NVS; SWX:NOVN). In all these trials, at least one dose of iloperidone had a statistically significant result compared to placebo, as did the...

Read the full 354 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >